

Carfilnat 60mg Injection (Carfilzomib)
Manufactured By
Natco Pharma Ltd
Pack Of
1
Salt Composition
Carfilzomib
Storage
Store between 2°C to 8°C in a refrigerator
ALL SUBSTITUTES
Overview
Carfilnat 60mg Injection is a prescription medicine containing carfilzomib. It is supplied in a 60mg injection presentation and belongs to the proteasome inhibitor class. It should be used only under the supervision of a clinician experienced in the relevant disease area.
Relapsed or refractory multiple myeloma: carfilzomib injection is used in adults who have received prior therapy, either as a single agent or in approved combinations. Current labeling includes combinations with dexamethasone, lenalidomide/dexamethasone, daratumumab/dexamethasone, daratumumab-hyaluronidase/dexamethasone, or isatuximab/dexamethasone in defined prior-treatment settings.
Carfilzomib 60mg injection irreversibly binds to active sites of the 20S proteasome within the 26S proteasome, inhibiting proteolytic activity. Proteasome inhibition disrupts protein homeostasis and can promote apoptosis in plasma cells, which have a high burden of protein production. The 60mg strength describes the commercial presentation; it does not automatically represent the complete prescribed dose. Dose and duration depend on diagnosis, treatment protocol, organ function, concomitant medicines, and treatment tolerance.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Brand name | Carfilnat |
| Generic / molecule | Carfilzomib |
| Strength | 60mg |
| Dosage form | Injection |
| Pack | 1 Vial |
| Manufacturer | Natco Pharma Ltd |
| Storage | Store between 2°C to 8°C in a refrigerator |
| Drug class | Proteasome inhibitor |
| Route of administration | Intravenous infusion |
| Prescription medicine | Yes |
| Self-administration | Only when appropriate for the dosage form and specifically prescribed; hospital-administered injections are not self-administered. |
Uses and Indications
Carfilnat 60mg injection may be prescribed in the following established clinical settings. The exact treatment line, combination regimen, and duration depend on the diagnosis, current labeling, and specialist assessment.
- Relapsed or refractory multiple myeloma: Carfilzomib 60mg is used in adults who have received prior therapy, either as a single agent or in approved combinations.
Current labeling includes combinations with dexamethasone, lenalidomide/dexamethasone, daratumumab/dexamethasone, daratumumab-hyaluronidase/dexamethasone, or isatuximab/dexamethasone in defined prior-treatment settings.
How Carfilnat 60mg Injection Works
Carfilzomib 60mg injection irreversibly binds to active sites of the 20S proteasome within the 26S proteasome, inhibiting proteolytic activity. Proteasome inhibition disrupts protein homeostasis and can promote apoptosis in plasma cells, which have a high burden of protein production.
Clinical Evidence for Carfilnat 60mg Injection
- Clinical evidence in this section relates to the Carfilzomib 60mg molecule and relevant treatment regimens; it should not be interpreted as evidence that every pivotal trial specifically studied the Carfilnat 60mg commercial presentation.
- Randomized studies support multiple carfilzomib injection-containing regimens in relapsed/refractory multiple myeloma.
- The clinical outcome depends on the partner drugs, prior treatment, cytogenetic risk, disease burden, and patient fitness.
- Evidence applies to carfilzomib injection regimens, not specifically to the Carfilnat 60mg commercial vial.
Side Effects of Carfilnat 60mg Injection
The side effects of Carfilzomib 60mg Injections vary by indication, dose, treatment duration, concomitant medicines, and individual patient factors. Common or clinically relevant effects include:
Common side effects
- Fatigue
- Weakness
- Low blood cell counts
- Nausea
- Vomiting
- Diarrhea
- Fever
Serious side effects
- Heart failure
- Infusion-related reactions
- Kidney and liver problems
- Neurological issues
Serious or persistent symptoms should be assessed promptly. The treating team should provide medicine-specific instructions on which symptoms require urgent medical attention.
Critical Safety Warning
- Carfilnat 60mg injection is a prescription medicine requiring appropriate medical supervision.
- Serious risks include cardiac failure, myocardial ischemia/infarction, sudden cardiac events, acute renal failure, tumor lysis syndrome, pulmonary toxicity, pulmonary hypertension, severe hypertension, venous thrombosis, infusion reactions, hemorrhage, thrombocytopenia, hepatic failure, thrombotic microangiopathy, and PRES.
- Hydration is important, particularly early in treatment, but must be balanced against volume overload and cardiac-failure risk.
- Older patients and patients with significant cardiac disease may require particularly careful assessment and follow-up.
Carfilnat 60mg Injection Dosage and How To Take It
These are molecule-level examples from regulatory labeling or established product information and are not instructions for self-dosing. The treating specialist determines the actual dose, schedule, dose modifications, and supportive medicines.
| Clinical situation | Dose |
|---|---|
| Once-weekly Kd/DKd example | 20mg/m² on Cycle 1 Day 1, then 70mg/m² if tolerated; 30-minute infusion on defined weekly cycle days. |
| Twice-weekly 20/56mg/m² regimen | 20mg/m² on Cycle 1 Days 1–2, then 56mg/m² if tolerated; 30-minute infusion on defined cycle days. |
| KRd / selected monotherapy schedule | 20mg/m² initially, then 27mg/m² if tolerated; protocol-specific 10-minute infusion schedule. |
| 60mg vial context | 60mg is a single-dose vial strength. Patient dose is calculated in mg/m²; for BSA >2.2m², current labeling caps dose calculation at 2.2m². |
Carfilnat 60mg Injection Missed Dose
Carfilnat Injection is given according to a scheduled treatment plan. If an appointment or dose is missed or delayed, contact the treating team promptly. Do not attempt to compensate for a missed carfilzomib 60mg dose or alter the treatment cycle without medical advice.
Safety Advice for Carfilnat 60mg Injection
| Category | Status | Guidance |
|---|---|---|
| Heart disease | High Caution | Alert your doctor regarding any pre-existing cardiovascular conditions. Cardiovascular status and any new conditions may require monitoring throughout the course of treatment. |
| Kidneys | Monitor | Carfilnat 60mg injection may cause complications with the kidneys. It can cause acute renal toxicity. It is advisable to monitor your kidney function and electrolyte balance throughout the treatment period. |
| Blood pressure | Monitor | The patient needs to have his blood pressure monitored throughout the treatment cycle, especially in patients with hypertension. |
| Pregnancy | Avoid | Carfilnat 60mg is highly toxic to an unborn child. Pregnancy testing is required before the treatment cycle starts, and contraceptive methods are required. |
| Hydration | Monitor | Proper hydration is needed to reduce any effects of the drug on the kidneys. Proper fluid management will depend on the patient's state. |
| Infusion reaction | High Caution | Severe allergic or infusion reactions may occur. Patients are monitored during treatment, and drugs are administered before starting treatment. |
Monitoring During Carfilnat 60mg Injection Treatment
Monitoring is individualized according to the disease and treatment regimen. It may include:
- CBC and platelets
- Renal function
- Blood pressure
- Cardiac symptoms/function when indicated
- Liver enzymes
- Tumor lysis parameters
- Infusion reactions
- Pulmonary symptoms
- Myeloma response markers
Carfilnat 60mg Injection Fact Box
| Parameter | Verified / publication wording |
|---|---|
| Brand | Carfilnat |
| Molecule | Carfilzomib |
| Strength | 60mg |
| Dosage form | Injection |
| Pack | 1 Vial |
| Manufacturer | Natco Pharma Ltd |
| Storage | Store between 2°C to 8°C in a refrigerator |
| Therapy type | Proteasome inhibitor |
| Route | Intravenous infusion |
| Prescription required | Yes |
| Dose principle | Indication/protocol-specific; do not infer the patient dose from pack strength |
| Medical supervision | Required |
Carfilnat 60mg Injection Drug Interactions
| Drug / Class | Risk | What To Do |
|---|---|---|
| Supplements and foods/herbal products | They may impact the safety or tolerance of the Carfilzomib 60mg Injection. | Review the complete medication, supplement, and relevant food/herbal product list before treatment. |
| Medication, supplement & herbal product | The combination may increase overlapping toxicities with heart, kidneys, blood clots, or bone marrow. | Review the entire myeloma protocol and watch for overlapping toxicities. |
| Thromboprophylaxis | Some of the partner drugs can raise the possibility of having thrombosis, and hence prophylactic measures are necessary. | Evaluate the need for thromboprophylaxis in the light of partner drugs. |
| Supportive medicines | The supportive medicines may lead to interactions and overlapping toxicities. | All supportive medications should be checked by the oncology pharmacist. |
FAQs About Carfilnat 60mg Injection
What is the Carfilnat 60mg Injection used for?
Carfilnat injection is employed for treating specific people with multiple myeloma by specialist-directed therapy. The particular application depends on individual disease status, prior treatments, and treatment combinations.
Is Carfilnat Injection the same as Carfilzomib 60mg?
Carfilzomib injection is the active substance, whereas Carfilnat 60mg is a commercial name or product.
What is Carfilzomib 60mg used for?
Carfilzomib 60mg Injection is the strength in vials for preparing the treatment. In 60mg strength, it does not indicate that each patient is provided with 60mg only as a total dosage. The actual dosage is defined by many clinical aspects and treatment combinations.
How does Carfilnat injection work?
Carfilnat Injection inhibits the proteasome, a cellular mechanism for processing proteins. Thus, it interferes with protein control in abnormal plasma cells.
Is Carfilzomib 60mg Injection chemotherapy?
Carfilzomib injection is an anticancer proteasome inhibitor. It is not an antiviral drug and does not fall under the umbrella of traditional cytotoxic chemotherapy drugs since it selectively inhibits the proteasome.
How is Carfilnat 60mg administered?
Carfilnat 60mg injection is administered by intravenous infusion by a healthcare provider. The dose, infusion duration, and the schedule vary depending on the protocol prescribed.
Does each patient get 60 mg exactly?
No, 60 mg refers to the strength of the vial. The prescribed dose varies depending on the protocol prescribed, among other factors.
What kind of monitoring is required while taking carfilzomib 60mg?
Monitoring could consist of blood counts, renal and hepatic function, blood pressure, signs and symptoms of heart and lung complications, and any other test that is part of your treatment protocol. The physicians will monitor any infusion complications and complications of the treatment itself.
Does Carfilnat 60mg Injection interact with other medications?
Carfilzomib injection can cause significant interactions or overlap in side effects with other medications. It is very important to inform the treating team of all prescribed drugs, over-the-counter medications, dietary supplements, and vitamins.
What do I need to tell my doctor before starting the Carfilzomib 60mg Injection?
Inform your physician about any kidney or liver dysfunction, heart disease, hypertension, reactions to previous treatments, any infections, pregnancy or pregnancy plans, nursing, allergy history, and any medication or supplements you are taking.
References
- DailyMed. KYPROLIS (carfilzomib) prescribing information https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6
- Current multiple-myeloma treatment guidelines https://themmrf.org/diagnosis-and-treatment/treatment-options/
- Current India-specific Carfizome package insert before publication https://5.imimg.com/data5/SELLER/Doc/2024/3/398991605/ZO/AM/AO/10833908/carfilzomib-injection-60mg.pdf
- BU.S. Food and Drug Administration. KYPROLIS (carfilzomib) Prescribing Information. FDA-approved prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202714s025lbl.pdf
- American Society of Clinical Oncology (ASCO). Multiple Myeloma Clinical Practice Guidelines. ASCO Guidelines https://ascopubs.org/guidelines/treatment-multiple-myeloma-asco-living-guideline?referrer=https%3A%2F%2Fwww.google.com%2F
Marketer Details
Natco Pharma Ltd
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.








